CN104204226A - 治疗癌症的方法 - Google Patents

治疗癌症的方法 Download PDF

Info

Publication number
CN104204226A
CN104204226A CN201380017091.3A CN201380017091A CN104204226A CN 104204226 A CN104204226 A CN 104204226A CN 201380017091 A CN201380017091 A CN 201380017091A CN 104204226 A CN104204226 A CN 104204226A
Authority
CN
China
Prior art keywords
patient
cancer
genotype
polymorphism
single nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380017091.3A
Other languages
English (en)
Chinese (zh)
Inventor
C.F.斯普拉格斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Osip Ray Ltd
Novartis AG
Original Assignee
SmithKline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Cork Ltd filed Critical SmithKline Beecham Cork Ltd
Publication of CN104204226A publication Critical patent/CN104204226A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201380017091.3A 2012-01-31 2013-01-31 治疗癌症的方法 Pending CN104204226A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261592893P 2012-01-31 2012-01-31
US61/592,893 2012-01-31
US201261654733P 2012-06-01 2012-06-01
US61/654,733 2012-06-01
PCT/EP2013/051865 WO2013113796A1 (en) 2012-01-31 2013-01-31 Method of treating cancer

Publications (1)

Publication Number Publication Date
CN104204226A true CN104204226A (zh) 2014-12-10

Family

ID=47714037

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380017091.3A Pending CN104204226A (zh) 2012-01-31 2013-01-31 治疗癌症的方法

Country Status (11)

Country Link
US (1) US20150023953A1 (enExample)
EP (2) EP3045543A3 (enExample)
JP (1) JP2015506955A (enExample)
KR (1) KR20140117644A (enExample)
CN (1) CN104204226A (enExample)
AU (1) AU2013214254B2 (enExample)
BR (1) BR112014019034A8 (enExample)
CA (1) CA2863287A1 (enExample)
IN (1) IN2014DN06127A (enExample)
RU (1) RU2014135224A (enExample)
WO (1) WO2013113796A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109504743A (zh) * 2017-09-13 2019-03-22 复旦大学附属华山医院 阿帕替尼有效生物标志物vegfr-2基因检测试剂盒

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115427456A (zh) * 2020-01-29 2022-12-02 得克萨斯州大学系统董事会 基于喹唑啉的酪氨酸激酶抑制剂在具有nrg1融合的癌症的治疗中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008088861A2 (en) * 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms predictive for dual tki therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5871918A (en) 1996-06-20 1999-02-16 The University Of North Carolina At Chapel Hill Electrochemical detection of nucleic acid hybridization
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
EP0897567A2 (en) 1996-04-19 1999-02-24 Spectra Biomedical, Inc. Correlating polymorphic forms with multiple phenotypes
EP0912559B1 (en) 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
KR100850389B1 (ko) 1999-06-25 2008-08-04 제넨테크, 인크. 인간화 항-ＥｒｂＢ2 항체 및 항-ＥｒｂＢ2 항체를 사용한치료 방법
KR100815681B1 (ko) 2000-06-30 2008-03-20 글락소 그룹 리미티드 퀴나졸린 디토실레이트 염 화합물
WO2007095038A2 (en) * 2006-02-09 2007-08-23 Novartis Ag Mutations and polymorphisms of erbb2
US20100104583A1 (en) * 2007-01-18 2010-04-29 University Of Southern California Gene Polymorphisms in VEGF and VEGF Receptor 2 as Markers for Cancer Therapy
EP1980626A1 (en) * 2007-04-13 2008-10-15 Het Nederlands Kanker Instituut Involvement of lipid kinase, and signal transduction pathway comprising said lipid kinase, in resistance to HER2-targeting therapy
WO2008128233A1 (en) * 2007-04-15 2008-10-23 University Of Chicago Methods and compositions concerning the vegfr-2 gene (kinase domain receptor, kdr)
ME02492B (me) * 2009-08-21 2017-02-20 Novartis Ag Lapatanib za lečenje kancera
WO2011060380A1 (en) * 2009-11-14 2011-05-19 The Regents Of The University Of California Pik3ca mutation status and sash1 expression predicts synergy between lapatinib and an akt inhibitor in her2 positive breast cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008088861A2 (en) * 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms predictive for dual tki therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KIM J J ET AL: "Role of VEGF and VEGFR2 single nucleotide polymorphisms in predicting treatment-induced hypertension and clinical outcome in metastatic clear cell RCC,patients treated with sunitinib", 《JOURNAL OF CLINICAL ONCOLOGY》 *
KIM JENNY J ET AL: "Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib", 《CANCER》 *
LURJE G ET AL: "VEGF AND VEGF receptor-2 gene polymorphisms predict tumor recurrence in stage II and III colon cancer", 《JOURNAL OF CLINICAL ONCOLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109504743A (zh) * 2017-09-13 2019-03-22 复旦大学附属华山医院 阿帕替尼有效生物标志物vegfr-2基因检测试剂盒

Also Published As

Publication number Publication date
IN2014DN06127A (enExample) 2015-08-14
BR112014019034A2 (enExample) 2017-06-20
WO2013113796A1 (en) 2013-08-08
US20150023953A1 (en) 2015-01-22
KR20140117644A (ko) 2014-10-07
BR112014019034A8 (pt) 2017-07-11
AU2013214254B2 (en) 2016-04-21
JP2015506955A (ja) 2015-03-05
EP3045543A2 (en) 2016-07-20
CA2863287A1 (en) 2013-08-08
AU2013214254A1 (en) 2014-08-14
RU2014135224A (ru) 2016-03-27
EP3045543A3 (en) 2016-10-12
EP2809805A1 (en) 2014-12-10

Similar Documents

Publication Publication Date Title
US9730925B2 (en) Methods of treating cancer
US20160361309A1 (en) Methods of treating cancer patients responding to ezh2 inhibitor gsk126
JP2011505145A5 (enExample)
JP2011505145A (ja) Ｖｅｇｆ多型および抗脈管形成治療
EP2115163A2 (en) Gene polymorphisms as sex-specific predictors in cancer therapy
US10004742B2 (en) Method of treating cancer
CN103930114A (zh) 给药和治疗方法
WO2014093750A1 (en) Method of administration and treatment
AU2013214254B2 (en) Method of treating cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20151026

Address after: Basel, Switzerland

Applicant after: NOVARTIS AG

Address before: London, England

Applicant before: Leo Osip Ray Ltd.

Effective date of registration: 20151026

Address after: London, England

Applicant after: Leo Osip Ray Ltd.

Address before: The Irish Village

Applicant before: SmithKline Beecham (Cork) Ltd.

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20141210